acc2501 |
Cdc2 |
phosphorylation |
Tyr15 |
human |
Ovarian Cancer |
HT29 |
Radiation |
Impairing |
4.5 (High)
|
11719452
|
acc2502 |
Cdc2 |
phosphorylation |
Thr14 |
human |
Colorectal Cancer |
HT29 |
Radiation |
Impairing |
4.5 (High)
|
11719452
|
acc2503 |
GSK3beta |
phosphorylation |
Ser9 |
human |
Endometrial Cancer |
RL95-2 |
Cisplatin |
Impairing |
5.0 (High)
|
33680959
|
acc2504 |
GSK3beta |
phosphorylation |
Ser9 |
human |
Endometrial Cancer |
ARK-2 |
Cisplatin |
Impairing |
5.0 (High)
|
33680959
|
acc2505 |
PKCepsilon |
phosphorylation |
Ser87 |
human |
Breast Cancer |
MCF7 |
4-OHE2 |
Associated |
4.0 (Moderate) |
31493422
|
acc2506 |
PKCepsilon |
phosphorylation |
Ser87 |
human |
Breast Cancer |
MDA-MB-231 |
4-OHE2 |
Associated |
4.0 (Moderate) |
31493422
|
acc2507 |
PKCepsilon |
phosphorylation |
Ser87 |
human |
Cervical Cancer |
HeLa |
4-OHE2 |
Associated |
4.0 (Moderate) |
31493422
|
acc2508 |
PKCepsilon |
phosphorylation |
Ser87 |
human |
Prostate Cancer |
PC3 |
4-OHE2 |
Associated |
4.0 (Moderate) |
31493422
|
acc2509 |
UVRAG |
phosphorylation |
Ser522 |
human |
Hepatocellular Carcinoma |
MHCC97H |
D4476 |
Associated |
4.0 (Moderate) |
30686098
|
acc2510 |
UVRAG |
phosphorylation |
Ser522 |
human |
Hepatocellular Carcinoma |
HuH-7 |
D4476 |
Associated |
4.0 (Moderate) |
30686098
|
acc2511 |
UVRAG |
ubiquitination |
Lys517 |
human |
Hepatocellular Carcinoma |
MHCC97H |
D4476 |
Associated |
4.0 (Moderate) |
30686098
|
acc2512 |
UVRAG |
ubiquitination |
Lys517 |
human |
Hepatocellular Carcinoma |
HuH-7 |
D4476 |
Associated |
4.0 (Moderate) |
30686098
|
acc2513 |
UVRAG |
ubiquitination |
Lys559 |
human |
Hepatocellular Carcinoma |
MHCC97H |
D4476 |
Associated |
4.0 (Moderate) |
30686098
|
acc2514 |
UVRAG |
ubiquitination |
Lys559 |
human |
Hepatocellular Carcinoma |
HuH-7 |
D4476 |
Associated |
4.0 (Moderate) |
30686098
|
acc2515 |
ITGalpha6 |
S-nitrosylation |
Cys86 |
human |
Prostate Cancer |
PC3 |
1400W(iNOS inhibitors) |
Associated |
4.0 (Moderate) |
23106339
|
acc2516 |
ITGalpha6 |
S-nitrosylation |
Cys86 |
human |
Prostate Cancer |
DU145 |
1400W(iNOS inhibitors) |
Associated |
4.0 (Moderate) |
23106339
|
acc2517 |
SOX10 |
sumoylation |
Lys55 |
human |
Melanoma |
|
Vemurafenib |
Impairing |
5.0 (High)
|
34087780
|
acc2518 |
LIP |
ubiquitination |
unclear |
mouse |
Mesothelioma |
AB1 |
Cisplatin |
Enhancing |
5.0 (High)
|
29748013
|
acc2519 |
LIP |
ubiquitination |
unclear |
human |
Mesothelioma |
|
Cisplatin |
Enhancing |
5.0 (High)
|
29748013
|
acc2520 |
PD-L1 |
ubiquitination |
unclear |
human |
Lung Cancer |
A549 |
DHA |
Associated |
4.0 (Moderate) |
36309154
|
acc2521 |
PD-L1 |
ubiquitination |
unclear |
mouse |
Lung Cancer |
LLC |
DHA |
Associated |
4.0 (Moderate) |
36309154
|
acc2522 |
PD-L1 |
ubiquitination |
unclear |
human |
Hepatocellular Carcinoma |
HepG2 |
DHA |
Associated |
4.0 (Moderate) |
36309154
|
acc2523 |
PD-L1 |
ubiquitination |
unclear |
human |
Hepatocellular Carcinoma |
SMMC-7721 |
DHA |
Associated |
4.0 (Moderate) |
36309154
|
acc2524 |
Stathmin |
phosphorylation |
Ser38 |
human |
Ovarian Cancer |
RMG-1 |
Paclitaxel |
Impairing |
5.0 (High)
|
36328498
|
acc2525 |
HER2 |
ubiquitination |
unclear |
human |
Breast Cancer |
SK-BR-3 |
Peptide p37 |
Associated |
4.0 (Moderate) |
25898135
|
acc2526 |
HER2 |
ubiquitination |
unclear |
human |
Breast Cancer |
BT474 |
Peptide p37 |
Associated |
4.0 (Moderate) |
25898135
|
acc2527 |
HER2 |
ubiquitination |
unclear |
human |
Breast Cancer |
ZR-75-30 |
Peptide p37 |
Associated |
4.0 (Moderate) |
25898135
|
acc2528 |
HER2 |
ubiquitination |
unclear |
human |
Breast Cancer |
MDA-MB-361 |
Peptide p37 |
Associated |
4.0 (Moderate) |
25898135
|
acc2529 |
HER2 |
ubiquitination |
unclear |
human |
Breast Cancer |
SK-BR-3 |
Peptide p37 + Trastuzumab |
Associated |
4.0 (Moderate) |
25898135
|
acc2530 |
JNK2 |
phosphorylation |
unclear |
human |
Colorectal Cancer |
HT29 |
TRAIL + 5-fluorouracil (5-FU) |
Enhancing |
5.0 (High)
|
15837763
|
acc2531 |
JNK2 |
phosphorylation |
unclear |
human |
Colorectal Cancer |
HepG2 |
TRAIL + 5-fluorouracil (5-FU) |
Enhancing |
5.0 (High)
|
15837763
|
acc2532 |
AMPK |
phosphorylation |
Thr172 |
human |
Hepatocellular Carcinoma |
HepG2 |
Berberine |
Associated |
3.0 (Low)
|
16508037
|
acc2533 |
AMPK |
phosphorylation |
Thr183 |
human |
Hepatocellular Carcinoma |
HepG2 |
Berberine |
Associated |
3.0 (Low)
|
16508037
|
acc2534 |
Nrf2 |
phosphorylation |
unclear |
human |
Neuroblastoma |
IMR-32 |
DMAT(CK2 inhibitor) |
Associated |
4.0 (Moderate) |
18273910
|
acc2535 |
MRP3 |
nitration |
unclear |
human |
Colorectal Cancer |
HT29 |
Doxorubicin |
Enhancing |
5.0 (High)
|
18922976
|
acc2536 |
MRP3 |
nitration |
unclear |
human |
Colorectal Cancer |
HT29-dx |
Doxorubicin |
Enhancing |
5.0 (High)
|
18922976
|
acc2537 |
AKT |
phosphorylation |
Thr308 |
human |
Colorectal Cancer |
HT29 |
SBA |
Associated |
4.0 (Moderate) |
20503249
|
acc2538 |
AKT |
phosphorylation |
Ser473 |
human |
Colorectal Cancer |
HT29 |
SBA |
Associated |
4.0 (Moderate) |
20503249
|
acc2539 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Hepatocellular Carcinoma |
Hep3B |
XZH-5 |
Impairing |
4.0 (Moderate) |
21311975
|
acc2540 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Hepatocellular Carcinoma |
HepG2 |
XZH-5 |
Impairing |
4.0 (Moderate) |
21311975
|
acc2541 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Hepatocellular Carcinoma |
HuH-7 |
XZH-5 |
Impairing |
4.0 (Moderate) |
21311975
|
acc2542 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Hepatocellular Carcinoma |
SNU-387 |
XZH-5 |
Impairing |
4.0 (Moderate) |
21311975
|
acc2543 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Hepatocellular Carcinoma |
SNU-398 |
XZH-5 |
Impairing |
4.0 (Moderate) |
21311975
|
acc2544 |
MKP-1 |
S-nitrosylation |
Cys258 |
human |
Head and Neck Cancer |
MDA-1483 |
Radiotherapy |
Impairing |
4.5 (High)
|
22014408
|
acc2545 |
MKP-1 |
S-nitrosylation |
Cys258 |
human |
Head and Neck Cancer |
UM-SCC-10A |
Radiotherapy |
Impairing |
4.5 (High)
|
22014408
|
acc2546 |
THOC5 |
phosphorylation |
Tyr225 |
human |
Leukemia |
K562 |
Dasatinib |
Enhancing |
5.0 (High)
|
23032722
|
acc2547 |
THOC5 |
phosphorylation |
Tyr225 |
human |
Leukemia |
K562 |
Imatinib |
Enhancing |
5.0 (High)
|
23032722
|
acc2548 |
THOC5 |
phosphorylation |
Tyr225 |
human |
Leukemia |
K562 |
Nilotinib |
Enhancing |
5.0 (High)
|
23032722
|
acc2549 |
ITGalpha6 |
S-nitrosylation |
Cys86 |
human |
Prostate Cancer |
PC3 |
1400W(iNOS inhibitors) |
Enhancing |
5.0 (High)
|
23106339
|
acc2550 |
AKT |
phosphorylation |
Thr308 |
human |
Neuroblastoma |
SK-N-SH neuroblastoma cells |
Okadaic acid |
Enhancing |
4.0 (Moderate) |
23127854
|